

Gina Mejía-a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6553865/publications.pdf>

Version: 2024-02-01

30
papers

796
citations

758635

12
h-index

525886

27
g-index

32
all docs

32
docs citations

32
times ranked

1642
citing authors

#	ARTICLE	IF	CITATIONS
1	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. <i>Pharmaceutics</i> , 2022, 15, 78.	1.7	8
2	Patients'™ Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 270.	1.1	3
3	Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. <i>Advances in Therapy</i> , 2022, 39, 1743-1753.	1.3	10
4	First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 124-135.	2.3	25
5	Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. <i>Human Psychopharmacology</i> , 2021, 36, 1-12.	0.7	10
6	Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. <i>Advances in Therapy</i> , 2021, 38, 1035-1054.	1.3	17
7	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111087.	2.5	12
8	Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2021, 60, 261-270.	1.6	12
9	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. <i>Journal of Personalized Medicine</i> , 2021, 11, 204.	1.1	19
10	Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. <i>Frontiers in Pharmacology</i> , 2021, 12, 660639.	1.6	1
11	Efficacy and safety of preoperative preparation with Lugol's iodine solution in euthyroid patients with Graves'™ disease (LIGRADIS Trial): Study protocol for a multicenter randomized trial. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100806.	0.5	0
12	Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. <i>Advances in Therapy</i> , 2021, 38, 4070-4081.	1.3	1
13	PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3772.	1.0	12
14	Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1573.	2.0	4
15	ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112083.	2.5	3
16	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. <i>Frontiers in Pharmacology</i> , 2021, 12, 718281.	1.6	4
17	Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. <i>Pharmaceutics</i> , 2021, 13, 2036.	2.0	8
18	Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. <i>Pharmacogenomics Journal</i> , 2020, 20, 235-245.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. BMC Pharmacology & Toxicology, 2020, 21, 54.	1.0	19
20	Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet, The, 2020, 395, 1705-1714.	6.3	347
21	Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. Pharmacogenomics, 2020, 21, 663-675.	0.6	8
22	Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors: A Population-Based Study in Spain. Frontiers in Pharmacology, 2020, 11, 734.	1.6	12
23	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Advances in Therapy, 2020, 37, 3537-3550.	1.3	16
24	The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. British Journal of Clinical Pharmacology, 2020, 86, 2051-2062.	1.1	19
25	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. Biomedicines, 2020, 8, 94.	1.4	57
26	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. BMJ Open, 2020, 10, e037443.	0.8	2
27	Polymorphisms in <i>CYP1A2</i> , <i>CYP2C9</i> and <i>ABCB1</i> affect agomelatine pharmacokinetics. Journal of Psychopharmacology, 2019, 33, 522-531.	2.0	36
28	Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. Clinical Therapeutics, 2019, 41, 2558-2570.e7.	1.1	31
29	Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 321-329.	1.2	39
30	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 474-485.	1.2	51